These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19098393)

  • 1. [Front-line drug discovery system for cancer].
    Mizukami T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
    Brachmann S; Fritsch C; Maira SM; García-Echeverría C
    Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer biomarkers: current issues and future directions.
    Jain KK
    Curr Opin Mol Ther; 2007 Dec; 9(6):563-71. PubMed ID: 18041667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.
    Workman P
    Cold Spring Harb Symp Quant Biol; 2005; 70():499-515. PubMed ID: 16869789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New approaches to molecular cancer therapeutics.
    Collins I; Workman P
    Nat Chem Biol; 2006 Dec; 2(12):689-700. PubMed ID: 17108987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to develop a successful cancer drug--molecules to medicines or targets to treatments?
    Newell DR
    Eur J Cancer; 2005 Mar; 41(5):676-82. PubMed ID: 15763642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genomic markers and anticancer chemotherapy].
    Nishiyama M
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress towards personalized medicine.
    Bates S
    Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From darkness to light with biomarkers in early clinical trials of cancer drugs.
    Carden CP; Banerji U; Kaye SB; Workman P; de Bono JS
    Clin Pharmacol Ther; 2009 Feb; 85(2):131-3. PubMed ID: 19151637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive medicine: incipient reality or fata morgana?
    Dietel M
    J Pathol; 2007 Aug; 212(4):353-5. PubMed ID: 17573671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy.
    Zhang E; Zhang C; Su Y; Cheng T; Shi C
    Drug Discov Today; 2011 Feb; 16(3-4):140-6. PubMed ID: 21182981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of drug discovery for personalized medicine.
    Jain KK
    Curr Opin Mol Ther; 2006 Dec; 8(6):487-92. PubMed ID: 17243483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.